Diabetes classification: Grey zones, sound and smoke: Action LADA 1

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 7, 2008, Pages 511-519

  Leslie, R D G ^a   Kolb, H ^b   Schloot, N C ^b   Buzzetti, R ^d   Mauricio, D ^e   De Leiva, A ^e   Yderstraede, K ^f   Sarti, C ^g   Thivolet, C ^h   Hadden, D ⁱ   Hunter, S ⁱ   Schernthaner, G ^j   Scherbaum, W ^b,c   Williams, R ^k   Pozzilli, P ^a,l  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ ROYAL VICTORIA HOSPITAL   (United Kingdom)

^j KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^k SWANSEA UNIVERSITY   (United Kingdom)

^l UNIVERSITY CAMPUS BIO MEDICO   (Italy)

more..

Author keywords

Age at onset of diabetes; GADA; Insulin resistance; Insulin secretion; Ketosis prone diabetes; LADA; Type 1 diabetes; Type 2 diabetes

Indexed keywords

GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE ANTIBODY; HLA ANTIGEN; HLA DQB1 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN G; INSULIN; PANCREAS ISLET CELL ANTIBODY; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; T LYMPHOCYTE ANTIGEN; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KETOACIDOSIS; KETOSIS PRONE DIABETES; LATENT AUTOIMMUNE DIABETES IN ADULTS; LONG TERM CARE; NOMENCLATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; T LYMPHOCYTE; ADULT; AUTOIMMUNE DISEASE; CLASSIFICATION; DIABETIC KETOACIDOSIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PANCREAS ISLET; SECRETION;

ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; GENETIC PREDISPOSITION TO DISEASE; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS;

EID: 58149168752     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.877     Document Type: Review

References (66)

1. Expert Committee on the diagnosis and Classification of Diabetes Mellitus. Report of the experts committee on the diagnosis and classification of Diabetes Mellitus. Diabetes Care 2003; 26: S5-S20.
2. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005; 54: 2503-2513.
3. Gale EAM. Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005; 48: 2195-2199.
4. Fajans SS, Bell GI. Phenotypic heterogeneity between different mutations of MODY subtypes and within MODY pedigrees. Diabetologia 2006; 49: 1106-1108.
5. Henriksen OM, Roder ME, Prahl JB, Svendsen OL. Diabetic ketoacidosis in Denmark Incidence and mortality estimated from public health registries. Diabetes Res Clin Pract 2007; 76: 51-56.
6. Balasubramanyam A, Garza G, Rodriquez LVN, et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care 2006; 29: 2575-2579.
7. Umpierrez GE, Woo W, Hagopian WA, et al. Immunogenetic analysis suggest different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. Diabetes Care 1999; 22: 1517-1523.
8. Mauvais-Jarvis F, Sobngwi E, Porcher R, et al. Ketosis-prone type 2 diabetes in patients of Sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes 2004; 53: 645-653.
9. Sobngwi E, Vexiau P, Levy V, et al. Metabolic and immunogenetic prediction of long-term insulin remission in African patients with atypical diabetes. Diabet Med 2002; 19: 832-835.
10. Banerji MA, Chaiken RL, Huey H, et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4: Flatbush diabetes. Diabetes 1994; 43: 741-745.
11. Linfoot P, Bergstrom C, Ipp E. Pathophysiology of ketoacidosis in Type 2 diabetes mellitus. Diabetes Med 2005; 22: 1414-1419.
12. Umpierrez GE. Ketosis-prone type 2 diabetes: time to revise the classification of diabetes. Diabetes Care 2006; 29: 2755-2757.
13. Peltonen L, McKusick VA. Genomics and medicine: Dissecting human disease in the postgenomic era. Science 2001; 291: 1224-1229.
14. Knowles MR, Durie PR. What is cystic fibrosis? N Engl J Med 2002; 347: 439-442.
15. Rosenstein BJ. Nonclassic cystic fibrosis: a clinical conundrum. Pediatr Pulmonol 2003; 36: 10-12.
16. Leslie RD, Williams R, Pozzilli P. Type 1 diabetes and latent autoimmune diabetes in adults (LADA): one end of the rainbow. J Clin Endocrinol Metab 2006; 91: 1654-1659.
17. Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP. Islet cell antibody-positive relatives with human leukocyte antigen DQA1* 0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1. J Clin Endocrinol Metab 2000; 85: 1255-1260.
18. Sabbah E, Savola K, Ebeling T, et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 2000; 23: 1326-1332.
19. Leslie RDG, Delli Castelli M. Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 2004; 53: 3033-3040.
20. Desai M, Zeggini E, Horton VA, et al. An association analysis of the HLA gene region in latent autoimmune diabetes in adults. Diabetologia 2007; 50: 68-73.
21. Horton V, Stratton I, Bottazzo GF, et al. Genetic heterogeneity of autoimmune diabetes: age at presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). Diabetologia 1999; 42: 608-616.
22. Maldonado M, Hampe CS, Gaur LK, et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functionsl classification, prosective analysis, and clinical outcomes. J Clin Endocrinol Metab 2003; 88: 5090-5098.
23. Torn C, Gupta M, Nikitina Zake L, Sanjeevi CB, Landin-Olsson M. Heterozygosity for MICA5.0/MICA5.1 and HLA-DR3-DQ2/DR4-DQ8 are independent genetic risk factors for latent autoimmune diabetes in adults. Hum Immunol 2003; 64: 902-909.
24. Van Autreve JE, Koeleman BP, Quartier E, et al, Belgian Diabetes Registry. MICA is associated with type 1 diabetes in the Belgian population, independent of HLA-DQ. Hum Immunol 2006; 67: 94-101.
25. Alizadeh BZ, Eerligh P, van der Slik AR, et al. MICA marks additional risk factors for Type 1 diabetes on extended HLA haplotypes: an association and meta-analysis. Mol Immunol 2007; 44: 2806-2812.
26. Desai M, Zeggini E, Horton VA, et al. The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults. Diabetes 2006; 55: 1890-1894.
27. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001; 108: 1417-1422.
28. Bingley PJ, Gale EA, The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006; 49: 881-890.
29. Turner R, Stratton I, Horton V, et al. Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes (UKPDS 25). Lancet 1997; 350: 1288-1293.
30. Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005; 48: 703-708.
31. Desai M, Cull CA, Horton VA, et al. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 2007; 50: 2052-2060.
32. Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes 2003; 52: 1128-1136.
33. Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48: 2206-2222.
34. Hosszufalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003; 26: 452-457.
35. Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005; 54: S62-S67.
36. Seissler J, de Sonnaville JJ, Morgenthaler NG, et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998; 41: 891-897.
37. Hampe CS, Kockum I, Landin-Olsson M. GAD65 antibody epitope patterns of type 1.5 diabetic patients are consistent with slow-onset autoimmune diabetes. Diabetes Care 2002; 25: 1481-1482.
38. Falorni A, Calcinaro F. Autoantibody profile and epitope mapping in latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002; 958: 99-106.
39. Padoa CJ, Banga JP, Madec AM, et al. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 2003; 52: 2689-2695.
40. Padoa CJ, Crowther NJ, Thomas JW, et al. Epitope analysis of insulin autoantibodies using recombinant Fab. Clin Exp Immunol 2005; 140: 564-571.
41. Hillman M, Torn C, Thorgeirsson H, Landin-Olsson M. IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes. Diabetologia 2004; 47: 1984-1989.
42. Buzzetti R, Di Pietro S, Giaccari A, et al, Non Insulin Requiring Autoimmuni Diabetes Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007; 30: 932-938.
43. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999; 48: 983-988.
44. Gambelunghe G, Forini F, Laureti S, et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol 2000; 52: 565-573.
45. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48: 150-157.
46. Kucera P, Novakova D, Behanova M, Novak J, Tlaskalova-Hogenova H, Andel M. Gliadin, endomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA). Clin Exp Immunol 2003; 133: 139-143.
47. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48: 1038-1350.
48. Yudkin JS. Insulin resistance and the metabolic syndrome-or the pitfalls of epidemiology. Diabetologia 2007; 50: 1576-1586.
49. Picardi A, Valorani MG, Vespasiani Gentilucci U, et al, IMDIAB Group. Raised C-reactive protein levels in patients with recent onset type 1 diabetes. Diabetes Metab Res Rev 2007; 23: 211-214.
50. Basu S, Larsson A, Vessby J, Vessby B, Berne C. Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care 2005; 28: 1371-1375.
51. Schölin A, Siegbahn A, Lind L, et al, Diabetes Incidence Study in Sweden group. CRP and IL-6 concentrations are associated with poor glycemic control despite preserved beta-cell function during the first year after diagnosis of type 1 diabetes. Diabetes Metab Res Rev 2004; 20: 205-210.
52. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003; 52: 1137-1142.
53. Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes 2007; 56: 1189-1197.
54. Rosario PWS, Reis JS, Amim R, et al. Comparison of clinical and laboratory characteristics between adult-onset type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care 2005; 28: 1803-1804.
55. Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993; 16: 902-910.
56. Behme MT, Dupre J, Harris SB, Hramiak IM, Mahon JL. Insulin resistance in latent autoimmune diabetes of adulthood. Ann N Y Acad Sci 2003; 1005: 374-377.
57. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004; 53: 3193-3200.
58. Chiu HK, Tsai EC, Juneja R, et al. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77: 237-244.
59. Thorn LM, Forsblom C, Fagerudd J, et al, FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28: 2019-2024.
60. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-1809.
61. Davis TM, Wright AD, Mehta ZM, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005; 48: 695-702.
62. Kobayashi T, Maruyama T, Shimada A. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann N Y Acad Sci 2002; 958: 117-130.
63. Zhou Z, Li X, Huang G, et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2005; 21: 203-208.
64. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19: 238-246.
65. Pozzilli P, Buzzetti R. A new expression of diabetes: double diabetes. Trends Endocrinol Metab 2007; 18: 52-57.
66. Bowker GC, Star SL. Sorting Things Out: Classification and Its Consequences. MIT Press: Cambridge; 1999.